Upcoming event

Tags

5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BCG, BCG therapy, BCG-unresponsive disease, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodality, Chemoradiotherapy, Clinical pathways, Clinical staging, Collaborative care, Comorbidity, Cystectomy, Early recurrence patterns, EAU21, EAU22, EMUC21, EMUC22, EORTC, ERBB2, ERCC2, ESMO21, ESOU21, ESOU22, Gene expression analysis, Guidelines, Hematuria, High-risk NMIBC, Highlight of the Month, Immune checkpoint, Immune checkpoint blockade, Immunoregulation, Immunotherapy, Intravesical therapy, Laparoscopic radical cystectomy, Masterclass, Masterclass on MIBC, Masterclass on NMIBC, Meta-analysis, Metastatic urothelial cancer, MIBC, Microscopic haematuria, Molecular subtypes, Multiparametric MRI, Neoadjuvant, Neoadjuvant chemotherapy, Neoplasm recurrence, Nephroureterectomy, NIBC, Non-visible haematuria, Nuclear matrix protein 22, Oncologic outcomes, Open radical cystectomy, Optical coherence, PD-L1, Pembrolizumab, PET, PLND, Postoperative complications, POUT trial, Prevention & control, Quality of life, Radical cystectomy, Radio-chemotherapy, Randomized controlled trial, RARC, RAZOR Trial, Recurrence, Robotic, Robotic prostatectomy, Robotic radical cystectomy, Robotic surgery, Surgical video, Surgical videos, Systematic review, Tomography, Transitional cell, Transitional cell carcinoma, Tregs, Urinary bladder neoplasms, Urinary diversion, Urological surgery, Urothelial cancer, Urothelium, UROwebinar, UTUC, Webinar
Show all

DaBlaCa-13 Study: Oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: Primary outcome of a randomized controlled trial

Journal of Clinical Oncology, October 2022

A randomized trial of PHOTOdynamic surgery in non–muscle-invasive bladder cancer

NEJM Evidence, September 2022

Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): A phase 2, open-label, randomised controlled trial

European Urology, August 2022

Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder

European Urology, August 2022

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial

The LANCET Oncology, April 2022

Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report

Journal of Urology, April 2022

Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial

Journal of Clinical Oncology, March 2022

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

Journal of Clinical Oncology, January 2022

Role of Lymphadenectomy During Radical Cystectomy for Non-muscle Invasive Bladder Cancer: Results From a Multi-Institutional Experience

Journal of Urology, October 2021

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

The New England Journal of Medicine, June 2021

Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?

European Urology, September 2021

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Lancet Oncol. , May 2021

Next